Elan Reisin, MD in Franklin, MI - Plastic Surgery

Elan Reisin, MD is a Plastic Surgery physician based in Franklin, Michigan. Elan Reisin is licensed to practice in Michigan (license number 000000000) and his current practice location is 24505 Franklin Farms Dr, Franklin, Michigan. He can be reached at his office (for appointments etc.) via phone at (202) 997-5007.

NPI number for Elan Reisin is 1013936376 and his current mailing address is 24505 Franklin Farms Dr, Franklin, Michigan. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1013936376.

Contact Information

	Elan Reisin, MD
	24505 Franklin Farms Dr, Franklin, MI 48025-2216
	(202) 997-5007
	Not Available

Physician's Profile

Full Name	Elan Reisin
Gender	Male
Speciality	Plastic Surgery
Location	24505 Franklin Farms Dr, Franklin, Michigan
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1013936376
Provider Enumeration Date: 07/18/2006
Last Update Date: 11/12/2013

Medical Identifiers

Medical identifiers for Elan Reisin such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1013936376	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208200000X	Plastic Surgery	000000000 (Michigan)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Elan Reisin is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Elan Reisin, MD 24505 Franklin Farms Dr, Franklin, MI 48025-2216 Ph: (202) 997-5007	Elan Reisin, MD 24505 Franklin Farms Dr, Franklin, MI 48025-2216 Ph: (202) 997-5007

News Archive

Cancer Research Technology and The Institute of Cancer Research complete licence with Vernalis

Cancer Research Technology Limited (CRT) and The Institute of Cancer Research announce that Vernalis plc has licensed exclusive worldwide rights to an anti-cancer Hsp90 inhibitor programme.

NanoString to begin clinical development program for Breast Cancer Intrinsic Subtyping Assay

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it is initiating the first in a series of studies to evaluate the clinical utility of the NanoString Breast Cancer Intrinsic Subtyping Assay.

Top experts focus on musculoskeletal disorders in open key Congress in Milan

Musculoskeletal conditions, which affect over 1.7 billion people worldwide, will be the focus of a major four-day Congress which opens today in Milan, Italy.

Cardiac rehab program may reduce death rate in women with coronary artery disease

Women with coronary artery disease who completed a 12-week cardiac rehabilitation program were two-thirds less likely to die compared to those who were not referred to the program.

Elan Reisin, MD - Plastic Surgery in Franklin, MI